David E. Burgio

791 total citations
18 papers, 576 citations indexed

About

David E. Burgio is a scholar working on Oncology, Pediatrics, Perinatology and Child Health and Orthopedics and Sports Medicine. According to data from OpenAlex, David E. Burgio has authored 18 papers receiving a total of 576 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 6 papers in Pediatrics, Perinatology and Child Health and 6 papers in Orthopedics and Sports Medicine. Recurrent topics in David E. Burgio's work include Bone health and treatments (8 papers), Bone health and osteoporosis research (6 papers) and Drug Transport and Resistance Mechanisms (5 papers). David E. Burgio is often cited by papers focused on Bone health and treatments (8 papers), Bone health and osteoporosis research (6 papers) and Drug Transport and Resistance Mechanisms (5 papers). David E. Burgio collaborates with scholars based in United States, France and Belgium. David E. Burgio's co-authors include Christian Roux, Steven Boonen, Patrick J. McNamara, Paul D. Miller, I Barton, Michael R. McClung, David D. Allen, Sun Dong Yoo, Robert A. Yokel and Artur Racewicz and has published in prestigious journals such as Journal of Pharmacology and Experimental Therapeutics, Journal of Bone and Mineral Research and Biochemical Pharmacology.

In The Last Decade

David E. Burgio

18 papers receiving 544 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David E. Burgio United States 14 354 328 145 107 86 18 576
Takako Hirota Japan 13 111 0.3× 241 0.7× 41 0.3× 181 1.7× 29 0.3× 32 703
G. M. Wilson United Kingdom 13 77 0.2× 91 0.3× 71 0.5× 100 0.9× 21 0.2× 25 521
María Marta Rivas Argentina 8 188 0.5× 151 0.5× 20 0.1× 98 0.9× 39 0.5× 21 498
Mary F. Carroll United States 7 68 0.2× 37 0.1× 60 0.4× 81 0.8× 8 0.1× 8 458
Xiaoli Li China 13 84 0.2× 19 0.1× 53 0.4× 73 0.7× 34 0.4× 41 411
Xinyi Tang China 12 58 0.2× 47 0.1× 12 0.1× 127 1.2× 16 0.2× 39 399
Frans Martens Netherlands 9 53 0.1× 12 0.0× 94 0.6× 91 0.9× 25 0.3× 15 447
H. C. Lee South Korea 10 38 0.1× 44 0.1× 27 0.2× 120 1.1× 17 0.2× 17 423
Marzieh Bakhshayeshkaram Iran 15 18 0.1× 105 0.3× 20 0.1× 93 0.9× 91 1.1× 29 538
I R Gunn United Kingdom 12 65 0.2× 15 0.0× 222 1.5× 41 0.4× 15 0.2× 16 396

Countries citing papers authored by David E. Burgio

Since Specialization
Citations

This map shows the geographic impact of David E. Burgio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David E. Burgio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David E. Burgio more than expected).

Fields of papers citing papers by David E. Burgio

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David E. Burgio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David E. Burgio. The network helps show where David E. Burgio may publish in the future.

Co-authorship network of co-authors of David E. Burgio

This figure shows the co-authorship network connecting the top 25 collaborators of David E. Burgio. A scholar is included among the top collaborators of David E. Burgio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David E. Burgio. David E. Burgio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
McClung, Michael R., José Zanchetta, Artur Racewicz, et al.. (2012). Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data. Osteoporosis International. 24(1). 293–299. 21 indexed citations
2.
McClung, Michael R., Ana Balske, David E. Burgio, Dietrich Wenderoth, & Robert R. Recker. (2012). Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years. Osteoporosis International. 24(1). 301–310. 33 indexed citations
3.
McClung, Michael R., Paul D. Miller, Jacques P. Brown, et al.. (2011). Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. Osteoporosis International. 23(1). 267–276. 27 indexed citations
4.
5.
Delmas, Pierre D., Michael R. McClung, José Zanchetta, et al.. (2007). Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone. 42(1). 36–42. 66 indexed citations
6.
Racewicz, Artur, et al.. (2007). Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study. Current Medical Research and Opinion. 23(12). 3079–3089. 4 indexed citations
7.
8.
Burgio, David E., et al.. (2003). Comparison of Daily (5 mg/day and 15 mg/day) Oral Dosing Regimens of Risedronate to Healthy Male and Female Volunteers. Clinical Pharmacology & Therapeutics. 73(2). 1 indexed citations
9.
Burgio, David E., et al.. (1998). Inhibition of brain choline uptake by isoarecolone and lobeline derivatives: implications for potential vector-mediated brain drug delivery. Neuroscience Letters. 258(1). 25–28. 13 indexed citations
10.
Miller, Edgar G., R. L. Bates, J M Bjorndahl, et al.. (1998). 16-Epiestriol, a Novel Anti-Inflammatory Nonglycogenic Steroid, Does Not Inhibit IFN-γ Production by Murine Splenocytes. Journal of Interferon & Cytokine Research. 18(11). 921–925. 2 indexed citations
11.
Burgio, David E., et al.. (1998). Effects of P-glycoprotein Modulators on Etoposide Elimination and Central Nervous System Distribution. Journal of Pharmacology and Experimental Therapeutics. 287(3). 911–917. 27 indexed citations
12.
Burgio, David E., Michael P. Gosland, & Patrick J. McNamara. (1996). Modulation effects of cyclosporine on etoposide pharmacokinetics and CNS distribution in the rat utilizing microdialysis. Biochemical Pharmacology. 51(7). 987–992. 16 indexed citations
13.
Oo, Charles, et al.. (1995). Pharmacokinetics of Caffeine and Its Demethylated Metabolites in Lactation: Predictions of Milk to Serum Concentration Ratios. Pharmaceutical Research. 12(2). 313–316. 20 indexed citations
14.
Yoo, Sun Dong, David E. Burgio, & Patrick J. McNamara. (1994). Phenobarbital Disposition in Adult and Neonatal Rabbits. Pharmaceutical Research. 11(8). 1204–1206. 3 indexed citations
15.
Yokel, Robert A., David D. Allen, David E. Burgio, & Patrick J. McNamara. (1992). Antipyrine as a dialyzable reference to correct differences in efficiency among and within sampling devices during in vivo microdialysis. Journal of Pharmacological and Toxicological Methods. 27(3). 135–142. 43 indexed citations
16.
McNamara, Patrick J., David E. Burgio, & Sun Dong Yoo. (1992). Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios.. Drug Metabolism and Disposition. 20(2). 302–308. 17 indexed citations
17.
McNamara, Patrick J., David E. Burgio, & Seung‐Wan Yoo. (1992). Pharmacokinetics of cimetidine during lactation: species differences in cimetidine transport into rat and rabbit milk.. Journal of Pharmacology and Experimental Therapeutics. 261(3). 918–923. 27 indexed citations
18.
McNamara, Patrick J., David E. Burgio, & Sun Dong Yoo. (1991). Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. Toxicology and Applied Pharmacology. 109(1). 149–160. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Takako Hirota Breakdown of academic impact, for papers by G. M. Wilson Breakdown of academic impact, for papers by María Marta Rivas Breakdown of academic impact, for papers by Mary F. Carroll Breakdown of academic impact, for papers by Xiaoli Li Breakdown of academic impact, for papers by Xinyi Tang Breakdown of academic impact, for papers by Frans Martens Breakdown of academic impact, for papers by H. C. Lee Breakdown of academic impact, for papers by Marzieh Bakhshayeshkaram Breakdown of academic impact, for papers by I R Gunn
Rankless by CCL
2026